The use of evinacumab was also evaluated in patients with refractory hypercholesterolemia, defined as an LDL-C level of 70 mg/dL or higher with clinical ASCVD or a level of 100 mg/dL or higher without clinical ASCVD and refractory to treatment with a PCSK9 inhibitor and a statin at a maximum tolerated dose, with or without ezetimibe; 72% of the sample had a diagnosis of HeFH [139]. Here, PCSK9 is linked to familial hypercholesterolemia.